Indian Biotech Industry exceeds $4B sales mark – (HEB, ARNA, FOLD, HALO)

Posted by on Dec 24, 2012

In 2012, the Biotech Industry in India generated revenue that has surpassed the $4-billion mark. The sector showed a growth of 18.5 per cent to hit Rs 20,440.70 crore. It is the first time, domestic revenue (Rs 10,599 crore) have exceeded export revenue (Rs 9,842 crore).

The sector’s growth rate in 2011 was 21.50 per cent with revenues hitting Rs 18,400 crore. Exports moved to Rs 8,852 crore and domestic revenue touched Rs 8,397 crore, said Bio-spectrum-ABLE Biotech Industry Survey 2012.

In United States, the year-to-date performance of SPDR S&P Biotech Index (NYSEARCA:XBI) stands at 33% year to date, reflecting that investment dollars are willingly flowing into the biotech sector.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) jumped about 27% on Friday after signing drug development deal with Pfizer Inc. (NYSE:PFE). The stock is currently trading 24.35% up its SMA 50. In the last trading session, its price moved -8.94% below its 200 day moving average, changing hands as low as $6.21 per share.

The worst hit in its 52 week range is $3.86 per share, with $13.50 being the 52 week best price, which compares with a latest closing price of $7.01. The Beta of this stock is 1.51.

On the flip side, the share price of Hemispherx BioPharma, Inc (NYSEAMEX:HEB) lost -22.22% during trading yesterday after a federal advisory panel voted 8 to 5 against the approval of rintatolimod to be used for the treatment of chronic fatigue syndrome, ending the day at $0.280.

At that price, the company has a market cap of $42.28 million. The stock has a 52 week worst hit of $0.19 and a 52 week high of $1.10. The P/S ratio is 211.41 and P/B ratio 1.17. The beta value is 1.22. HEB’s RSI amounts to 22.10.

The market value of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is $1.88 billion. It has 255 people in workforce, over the last 12 months has generated revenue of $27.73 million and has earnings of -$90.70 million. The firm’s operating margin is -221.81 percent and net profit margin -316.94 percent. The latest closing price of its shares moved down -1.81% from the 50-day moving average.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) continued to extend fall after Fabry drug failed late-stage study. For this company, a return on equity of -83.55 percent has been realized due to the financial position. Last twelve months per-share profit reached a value of -$1.13. The stock closed at $2.76, down -0.30 points or -9.80% from previous close and at a distance of -48.96% from 20-day simple moving average.

 

Leave a Reply